S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Foot Locker Builds Up Another Head of Steam; Gains Imminent
Average long-term US mortgage rate falls slightly, easing borrowing costs for home shoppers
Walgreens books hefty charge as the drugstore chain adjusts the value of struggling clinics
NASDAQ:AXNX

Axonics (AXNX) Stock Price, News & Analysis

$68.97
+0.07 (+0.10%)
(As of 03/28/2024 ET)
Today's Range
$68.88
$69.00
50-Day Range
$67.38
$68.97
52-Week Range
$47.59
$69.68
Volume
743,971 shs
Average Volume
944,498 shs
Market Capitalization
$3.52 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$70.73

Axonics MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
2.5% Upside
$70.73 Price Target
Short Interest
Bearish
5.76% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.38
Upright™ Environmental Score
News Sentiment
1.08mentions of Axonics in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$5.56 M Sold Last Quarter
Proj. Earnings Growth
106.67%
From $0.30 to $0.62 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.12 out of 5 stars

Medical Sector

204th out of 939 stocks

Surgical & Medical Instruments Industry

21st out of 97 stocks

AXNX stock logo

About Axonics Stock (NASDAQ:AXNX)

Axonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.

AXNX Stock Price History

AXNX Stock News Headlines

Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Axonics Responds to ITC Action by Medtronic
Beyond The Numbers: 7 Analysts Discuss Axonics Stock
Claim Your Complimentary Bitcoin Reward
Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.
Axonics just downgraded at Morgan Stanley, here's why
Axonics just downgraded at Truist, here's why
Axonics just downgraded at CL King, here's why
Axonics just downgraded at Leerink, here's why
Analyst Scoreboard: 5 Ratings For Axonics
Axonics just downgraded at RBC Capital, here's why
Why Is Axonics (AXNX) Stock Up 20% Today?
See More Headlines
Receive AXNX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Axonics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/28/2024
Today
3/29/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Surgical & medical instruments
Sub-Industry
N/A
Current Symbol
NASDAQ:AXNX
Employees
797
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$70.73
High Stock Price Target
$75.00
Low Stock Price Target
$63.00
Potential Upside/Downside
+2.5%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
13 Analysts

Profitability

Net Income
$-6,090,000.00
Pretax Margin
-2.39%

Debt

Sales & Book Value

Annual Sales
$366.38 million
Cash Flow
$0.13 per share
Book Value
$12.59 per share

Miscellaneous

Free Float
50,059,000
Market Cap
$3.52 billion
Optionable
Optionable
Beta
0.57
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives


AXNX Stock Analysis - Frequently Asked Questions

Should I buy or sell Axonics stock right now?

13 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Axonics in the last twelve months. There are currently 8 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" AXNX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AXNX, but not buy additional shares or sell existing shares.
View AXNX analyst ratings
or view top-rated stocks.

What is Axonics' stock price target for 2024?

13 Wall Street analysts have issued 1 year target prices for Axonics' stock. Their AXNX share price targets range from $63.00 to $75.00. On average, they anticipate the company's stock price to reach $70.73 in the next year. This suggests a possible upside of 2.5% from the stock's current price.
View analysts price targets for AXNX
or view top-rated stocks among Wall Street analysts.

How have AXNX shares performed in 2024?

Axonics' stock was trading at $62.23 on January 1st, 2024. Since then, AXNX shares have increased by 10.8% and is now trading at $68.97.
View the best growth stocks for 2024 here
.

When is Axonics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our AXNX earnings forecast
.

How were Axonics' earnings last quarter?

Axonics, Inc. (NASDAQ:AXNX) issued its quarterly earnings results on Wednesday, February, 28th. The company reported $0.13 earnings per share for the quarter, beating the consensus estimate of $0.06 by $0.07. The firm had revenue of $109.70 million for the quarter, compared to the consensus estimate of $107.33 million. Axonics had a negative trailing twelve-month return on equity of 1.00% and a negative net margin of 1.66%. Axonics's revenue for the quarter was up 27.7% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.01 earnings per share.

What guidance has Axonics issued on next quarter's earnings?

Axonics issued an update on its fourth quarter 2023 earnings guidance on Monday, January, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $109.3 million-$109.7 million, compared to the consensus revenue estimate of $105.5 million.

What is Raymond W. Cohen's approval rating as Axonics' CEO?

20 employees have rated Axonics Chief Executive Officer Raymond W. Cohen on Glassdoor.com. Raymond W. Cohen has an approval rating of 89% among the company's employees. 73.0% of employees surveyed would recommend working at Axonics to a friend.

What other stocks do shareholders of Axonics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Axonics investors own include RTX (RTX), Oasis Petroleum (OAS), Pfizer (PFE), Procter & Gamble (PG), Thermo Fisher Scientific (TMO), Cisco Systems (CSCO), CVS Health (CVS), AT&T (T) and Abbott Laboratories (ABT).

When did Axonics IPO?

Axonics (AXNX) raised $100 million in an initial public offering on Wednesday, October 31st 2018. The company issued 6,700,000 shares at a price of $14.00-$16.00 per share. BofA Merrill Lynch and Morgan Stanley acted as the underwriters for the IPO and Wells Fargo Securities and SunTrust Robinson Humphrey were co-managers.

Who are Axonics' major shareholders?

Axonics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.38%), Vanguard Group Inc. (10.32%), Bellevue Group AG (3.62%), Mackenzie Financial Corp (2.47%), Artisan Partners Limited Partnership (2.41%) and Dimensional Fund Advisors LP (1.82%). Insiders that own company stock include Alfred J Ford Jr, Danny L Dearen, Esteban Lopez, Jane E Kiernan, John Woock, Karen Noblett, Kari Leigh Keese, Raymond W Cohen, Raymond W Cohen and Rinda Sama.
View institutional ownership trends
.

How do I buy shares of Axonics?

Shares of AXNX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:AXNX) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners